Attacking Tumors at the Source

Our technology provides a new opportunity to “drug the undruggable”. We target specific protein-protein interactions, which when disrupted can lead to a “pro-cell death” fate or modulated immune response in targeted cells.

View Our Platform

Enabling Treatments Aimed at Dysregulated PPIs

Our lead candidate, ST101, is a cell-penetrating peptide antagonist of C/EBPβ designed to target various solid tumors (including breast cancer, melanoma, prostate cancer, GBM, lung cancer, and AML) and hematologic malignancies.

In July 2020, we initiated the first clinical trial for ST101, which has also been granted Orphan Drug Designation for the treatment of glioma and AML by the U.S. FDA.

More About ST101

Latest News

Sapience Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of ST101

Sapience Therapeutics Receives FDA Fast Track Designation for ST101 for Advanced Cutaneous Melanoma

Sapience Therapeutics Announces Multiple Poster Presentations on ST101 at the 2021 San Antonio Breast Cancer Symposium

Sapience Therapeutics Receives FDA Fast Track Designation for ST101 for the Treatment of Recurrent Glioblastoma Multiforme (GBM)

Sapience Therapeutics to Present at the RBC Capital Markets Healthcare Private Company Conference

Sapience Therapeutics to Present at the Piper Sandler 33rd Annual Healthcare Conference

Sapience Therapeutics Announces Multiple Poster Presentations on ST101 at 28th Prostate Cancer Foundation Annual Scientific Retreat and 18th International Congress of the Society for Melanoma Research

Sapience Therapeutics Awarded SBIR Grant from National Cancer Institute (NCI) of the National Institutes of Health (NIH) for ST316, its β-catenin antagonist peptide (BCAP) Program

Sapience Therapeutics Announces Oral Presentation on ST101 at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics 2021

Email Alerts

Stay informed and receive company updates straight to your inbox.

Sign up today